Mosaic ImmunoEngineering (CPMV) Total Non-Current Liabilities (2011 - 2023)
Mosaic ImmunoEngineering (CPMV) posted quarterly Total Non-Current Liabilities of $5.4 million for Q1 2023, up 44.84% year-over-year from $3.7 million in Q1 2022, and up 5.76% quarter-over-quarter from $5.1 million in Q4 2022.
Mosaic ImmunoEngineering (CPMV) Total Non-Current Liabilities (2011 - 2023) Analysis & Trends
Mosaic ImmunoEngineering's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $5.4 million for Q1 2023.
- In Q1 2023, Total Non-Current Liabilities rose 44.84% year-over-year to $5.4 million; the TTM figure through Mar 2023 stood at $5.4 million (up 44.84% YoY), while the FY2022 annual figure was $5.1 million, up 72.03% from the prior year.
- Total Non-Current Liabilities for Q1 2023 stood at $5.4 million, up from $5.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $5.4 million in Q1 2023, with the low at $274923.0 in Q3 2020.
- The 4-year median for Total Non-Current Liabilities is $3.0 million (2021), against an average of $3.0 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 226.84% in 2022, then jumped 44.84% in 2023.
- Mosaic ImmunoEngineering's Total Non-Current Liabilities stood at $771920.0 in 2020, then jumped by 284.0% to $3.0 million in 2021, then surged by 72.03% to $5.1 million in 2022, then increased by 5.76% to $5.4 million in 2023.
- Business Quant data shows CPMV's Total Non-Current Liabilities at $5.4 million in Q1 2023, $5.1 million in Q4 2022, and $4.7 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Mosaic ImmunoEngineering | 527,536.97 | 527,536.97 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 5.39 Mn |
| Dec 31, 2022 | 5.10 Mn |
| Sep 30, 2022 | 4.74 Mn |
| Jun 30, 2022 | 4.38 Mn |
| Mar 31, 2022 | 3.72 Mn |
| Dec 31, 2021 | 2.96 Mn |
| Sep 30, 2021 | 2.54 Mn |
| Jun 30, 2021 | 2.01 Mn |
| Mar 31, 2021 | 1.14 Mn |
| Nov 30, 2020 | 771,920.00 |
| Aug 31, 2020 | 274,923.00 |
| May 31, 2011 | 575,577.00 |